Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
NCT ID NCT06762080
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase I/II trial tests a combination of two drugs injected directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes surrounding the brain and spinal cord. The drugs are a bispecific antibody (cadonilimab) that targets two immune checkpoints (PD-1 and CTLA-4) and the chemotherapy drug pemetrexed. The study aims to find the safest dose and evaluate whether this treatment can control the disease in patients with solid tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a bispecific antibody (cadonilimab) that targets PD-1 and CTLA-4, combined with the chemotherapy drug pemetrexed, both injected into the spinal fluid
- What this could lead to
- If successful, this approach could offer a new treatment option for leptomeningeal metastasis, a fatal complication of cancer that currently has few effective therapies.
- What could go wrong
- This is an early-phase trial with only 36 participants, so the benefits are uncertain. The treatment involves direct injection into the spinal fluid and carries risks of serious neurological side effects like chemical meningitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Chest Hospital, Capital Medical University
Beijing, 101100, China
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, 516000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Triple therapy targets tough brain metastases in lung cancer
- New hope for lung cancer patients with brain-spread disease
- New hope for lung cancer patients with brain spread: targeted pill under study
- New drug combo targets brain tumors with genetic flaw